Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
CNR Ibb | back to homepage
▲NavBar
Ricerca avanzata▼
Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type (6 visite) (PDF pubblico 4 visite)

Hill BS, Sarnella A, Capasso D, Comegna D, Del Gatto A, Gramanzini M, Albanese S, Saviano M, Zaccaro L, Zannetti A

Cancers (ISSN: 2072-6694linking), 2019 Jan 24; 11(2): N/D-N/D.



Tipo di articolo: Journal Article,

Impact factor: 5.326, Impact factor a 5 anni: 0

Url: Non disponibile.

Parole chiave: Cell Migration And Invasion, Epithelial-Mesenchymal Transition, Stemness, Triple-Negative Breast Cancer, Alphavbeta3 Integrin, Psirgdechi,

Affiliazioni:

*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. billy.hill@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. achiara.sarnella@gmail.com., Dipartimento di Farmacia, Universita degli Studi di Napoli "Federico II", 80131 Naples, Italy. domenica.capasso@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. daniela.comegna@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. annarita.delgatto@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. matteo.gramanzini@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. sandra.albanese@ibb.cnr.it., Istituto di Cristallografia-CNR, 70126 Bari, Italy. msaviano@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. lzaccaro@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. antonella.zannetti@cnr.it.,


Riferimenti:

Non disponibile.

The mesenchymal sub-type of triple negative breast cancer (MES-TNBC) has a highly aggressive behavior and worse prognosis, due to its invasive and stem-like features, that correlate with metastatic dissemination and resistance to therapies. Furthermore, MES-TNBC is characterized by the expression of molecular markers related to the epithelial-to-mesenchymal transition (EMT) program and cancer stem cells (CSCs). The altered expression of alphavbeta(3) integrin has been well established as a driver of cancer progression, stemness, and metastasis. Here, we showed that the high levels of alphavbeta(3) are associated with MES-TNBC and therefore exploited the possibility to target this integrin to reduce the aggressiveness of this carcinoma. To this aim, MES-TNBC cells were treated with a novel peptide, named psiRGDechi, that we recently developed and characterized for its ability to selectively bind and inhibit alphavbeta(3) integrin. Notably, psiRGDechi was able to hamper adhesion, migration, and invasion of MES-TNBC cells, as well as the capability of these cells to form vascular-like structures and mammospheres. In addition, this peptide reversed EMT program inhibits mesenchymal markers. These findings show that targeting alphavbeta(3) integrin by psiRGDechi, it is possible to inhibit some of the malignant properties of MES-TNBC phenotype.
Nessun risultato.

Ricerca avanzata▼
Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]
Vai a fine pagina   Versione per copia e incolla facile   Esporta tutto in BibTeX   Esporta tutto in EndNote


Bolzati C, Salvarese N, Carpanese D, Seraglia R, Melendez-alafort L, Rosato A, Capasso D, Saviano M, Del Gatto A, Comegna D, Zaccaro L
* [(99m)Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of alphavbeta3 Integrin: Synthesis, Structure-Activity and Pharmacokinetic Studies (20 visite)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print, 1520-4804electronic), 2018 Nov 8; 61(21): 9596-9610.
Impact Factor: 6.253
Dettagli    Esporta in BibTeX    Esporta in EndNote

Camorani S, Hill B, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L
* Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer (136 visite) (PDF 23 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic, 1838-7640linking), 2018 Oct 6; 8(18): 5178-5199.
Impact Factor: 8.537
Dettagli    Esporta in BibTeX    Esporta in EndNote

Comegna D, Zannetti A, Del Gatto A, De Paola I, Russo L, Di Gaetano S, Liguoro A, Capasso D, Saviano M, Zaccaro L
* Chemical Modification for Proteolytic Stabilization of the Selective alphavbeta3 Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells (333 visite) (PDF 81 visite)
J MED CHEM (ISSN: 0022-2623), 2017 Dec 14; 60(23): 9874-9884.
Impact Factor: 6.253
Dettagli    Esporta in BibTeX    Esporta in EndNote

Depalo N, Corricelli M, De Paola I, Valente G, Iacobazzi RM, Altamura E, Debellis D, Comegna D, Fanizza E, Denora N, Laquintana V, Mavelli F, Striccoli M, Saviano M, Agostiano A, Del Gatto A, Zaccaro L, Curri ML
* NIR Emitting Nanoprobes Based on Cyclic RGD Motif Conjugated PbS Quantum Dots for Integrin-Targeted Optical Bioimaging (53 visite) (PDF 60 visite)
ACS APPL MATER INTER (ISSN: 1944-8244), 2017 Dec 13; 9(49): 43113-43126.
Impact Factor: 8.097
Dettagli    Esporta in BibTeX    Esporta in EndNote

Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A
* Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRbeta Aptamer (324 visite) (PDF 104 visite)
THERANOSTICS (ISSN: 1838-7640), 2017 Aug 22; 7(14): 3595-3607.
Impact Factor: 8.537
Dettagli    Esporta in BibTeX    Esporta in EndNote

Hill BS, Pelagalli A, Passaro N, Zannetti A
* Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype (74 visite)
Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2017 Aug 14; 8(42): 73296-73311.
Impact Factor: 5.168
Dettagli    Esporta in BibTeX    Esporta in EndNote

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L
* Aptamer-mediated impairment of EGFR-integrin alphavbeta3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (71 visite) (PDF 105 visite)
SCI REP-UK (ISSN: 2045-2322), 2017 Apr 20; 7: 46659-46659.
Impact Factor: 4.122
Dettagli    Esporta in BibTeX    Esporta in EndNote

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
* A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion (578 visite) (PDF 171 visite)
CANCER LETT (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.
Impact Factor: 5.992
Dettagli    Esporta in BibTeX    Esporta in EndNote

Romano S, Staibano S, Greco A, Brunetti A, Nappo G, Ilardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo M, Bisogni R, Scalvenzi M, Alfano B, Romano MF
* FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential (116 visite) (PDF 130 visite)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2013 Apr 4; 4(6): e578-e578.
Impact Factor: 5.333
Dettagli    Esporta in BibTeX    Esporta in EndNote

Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
* In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells (111 visite)
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Impact Factor: 1.045
Dettagli    Esporta in BibTeX    Esporta in EndNote

Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G
* Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit (120 visite)
J Transl Med Journal Of Translational Medicine (ISSN: 1479-5876electronic), 2011 Jan 13; 9: 7-7.
Impact Factor: 3.474
Dettagli    Esporta in BibTeX    Esporta in EndNote



11 Records (10 escludendo Abstract e Conferenze).
Impact factor totale: 62.811 (57.478 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 63.243 (57.91 escludendo Abstract e Conferenze).







    Esporta in BibTeX    Esporta in EndNote